PALISADE BIO, INC.
Close on Oct 19, 2026
- Market cap
- $283.25M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | $500.00K | $-0.05 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | After market close | – | $-0.05 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | After market close | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Mar 23, 2021 | After market close | – | – | – |
| Q3 FY2020 Ended Sep 30, 2020 | Nov 16, 2020 | After market close | – | – | – |
| Q2 FY2020 Ended Jun 30, 2020 | Aug 14, 2020 | During market hours | – | – | – |
| Q1 FY2020 Ended Mar 31, 2020 | Apr 2, 2020 | During market hours | – | – | – |
| Q3 FY2019 Ended Sep 30, 2019 | Nov 15, 2019 | During market hours | – | – | – |
| Q2 FY2019 Ended Jun 30, 2019 | Aug 14, 2019 | During market hours | – | – | – |
| Q1 FY2019 Ended Mar 31, 2019 | May 14, 2019 | After market close | – | – | – |
| Q4 FY2018 Ended Dec 31, 2018 | Mar 22, 2019 | After market close | – | – | – |
| Q3 FY2018 Ended Sep 30, 2018 | Nov 16, 2018 | Before market open | – | – | – |
Press releases
Announcements Palisade Bio filed with the SEC
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
Results of operations · EX-99.1 to Form 8-K
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Results of operations · EX-99.1 to Form 8-K
Bio Announces Cancellation of Special Meeting of Stockholders
Other events · EX-99.1 to Form 8-K
Bio Announces Exercise of Previously Issued Warrants for $3.9 Million
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors
Executive or director change · Other events · EX-99.2 to Form 8-K
DRAFT NOT FOR IMMEDIATE RELEASE
Material agreement · Unregistered share sale · Other events · EX-99.01 to Form 8-K
DRAFT NOT FOR IMMEDIATE RELEASE
Material agreement · Unregistered share sale · Other events · EX-99.02 to Form 8-K
Bio Appoints Margery Fischbein to its Board of Directors
Executive or director change · Other events · EX-99.01 to Form 8-K
Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
Bio Announces 1-for-15 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.01 to Form 8-K
Bio Reports Year End 2023 Financial Results and Provides Corporate Update
Results of operations · Listing notice · Shareholder vote results · EX-99.01 to Form 8-K
Bio Provides Corporate Update and Reiterates Guidance
Executive or director change · Other events · EX-99.01 to Form 8-K
Bio Announces Exercise of Previously Issued Warrants for $2.5 Million
Material agreement · Unregistered share sale · Other events · EX-99.01 to Form 8-K
Bio Announces Positive Preclinical Data of Lead Program
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.01 to Form 8-K
Regulation FD disclosure · EX-99.01 to Form 8-K
Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.01 to Form 8-K
Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.01 to Form 8-K
Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates
Material agreement · Acquisition or disposition completed · Other events · EX-99.01 to Form 8-K
Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.01 to Form 8-K
Bio Promotes Robert McRae to Chief Operating Officer
Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.01 to Form 8-K
Bio Announces Closing of $2.5 Million Registered Direct Offering
Material agreement · Unregistered share sale · Other events · EX-99.02 to Form 8-K
Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions
Other events · EX-99.01 to Form 8-K
Bio Announces Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.01 to Form 8-K
Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on Advancement of Lead Clinical Program, LB1148
Exit or restructuring costs · Regulation FD disclosure · EX-99.01 to Form 8-K
Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Palisade Bio Announces Closing of $13.8 Million Upsized Underwritten Public Offering and Full Exercise of Over-Allotment Option
Material agreement · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
Palisade Bio Announces $2.0 Million Registered Direct Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Restoring Intestinal Barrier Health Corporate Presentation | May 2022 PALI (NASDAQ) | palisadebio.com
Regulation FD disclosure · EX-99.1 to Form 8-K
Restoring Intestinal Barrier Health SAGES 2022 Presentation | March 16, 2022 PALI (NASDAQ) | palisadebio.com
Regulation FD disclosure · EX-99.1 to Form 8-K
Restoring Intestinal Barrier Health Corporate Presentation | February 2022 PALI (NASDAQ) | palisadebio.com
Regulation FD disclosure · EX-99.1 to Form 8-K
Restoring Intestinal Barrier Health Corporate Presentation | January 2022 PALI (NASDAQ) | palisadebio.com
Regulation FD disclosure · EX-99.1 to Form 8-K
| October 2021 PALI (NASDAQ) | palisadebio.com
Regulation FD disclosure · EX-99.1 to Form 8-K
Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the treatment of Central Nervous System Disorders
Other events · EX-99.01 to Form 8-K